Lerner SP - Search Results

1

Author Correction: Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic disease.

Rose KM, Huelster HL, Meeks JJ, Faltas BM, Sonpavde GP, Lerner SP, Ross JS, Spiess PE, Grass GD, Jain RK, Kamat AM, Vosoughi A, Wang L, Wang X, Li R. Rose KM, et al. Among authors: lerner sp. Nat Rev Urol. 2023 Jul;20(7):452. doi: 10.1038/s41585-023-00783-6. Nat Rev Urol. 2023. PMID: 37217696 No abstract available.

2

Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic disease.

Rose KM, Huelster HL, Meeks JJ, Faltas BM, Sonpavde GP, Lerner SP, Ross JS, Spiess PE, Grass GD, Jain RK, Kamat AM, Vosoughi A, Wang L, Wang X, Li R. Rose KM, et al. Among authors: lerner sp. Nat Rev Urol. 2023 Jul;20(7):406-419. doi: 10.1038/s41585-023-00725-2. Epub 2023 Mar 28. Nat Rev Urol. 2023. PMID: 36977797 Review.

3

Tumor Subtyping: Making Sense of Heterogeneity with a Goal Toward Treatment.

Meeks JJ, Sjödahl G, Lerner SP, Das A, McConkey DJ, Black PC. Meeks JJ, et al. Among authors: lerner sp. Bladder Cancer. 2021 Mar 19;7(1):1-11. doi: 10.3233/BLC-200306. eCollection 2021. Bladder Cancer. 2021. PMID: 38993221 Free PMC article. Review.

4

Bacillus Calmette-Guérin vaccination as defense against SARS-CoV-2 (BADAS): a randomized controlled trial to protect healthcare workers in the USA by enhanced trained immune responses.

DiNardo AR, Arditi M, Kamat AM, Koster KJ, Carrero S, Nishiguchi T, Lebedev M, Benjamin AB, Avalos P, Lozano M, Moule MG, McCune B, Herron B, Ladki M, Sheikh D, Spears M, Herrejon IA, Dodge C, Kumar S, Hutchison RW, Ofili TU, Opperman LA, Bernard JA, Lerner SP, Udeani G, Neal G, Netea MG, Cirillo JD. DiNardo AR, et al. Among authors: lerner sp. Trials. 2023 Oct 4;24(1):636. doi: 10.1186/s13063-023-07662-w. Trials. 2023. PMID: 37794431 Free PMC article. Clinical Trial.

5

Comprehensive molecular characterization of urothelial bladder carcinoma.

Cancer Genome Atlas Research Network. Cancer Genome Atlas Research Network. Nature. 2014 Mar 20;507(7492):315-22. doi: 10.1038/nature12965. Epub 2014 Jan 29. Nature. 2014. PMID: 24476821 Free PMC article.

6

Characterizing treatment resistance in muscle invasive bladder cancer using the chicken egg chorioallantoic membrane patient-derived xenograft model.

Villanueva H, Wells GA, Miller MT, Villanueva M, Pathak R, Castro P, Ittmann MM, Sikora AG, Lerner SP. Villanueva H, et al. Among authors: lerner sp. Heliyon. 2022 Dec 24;8(12):e12570. doi: 10.1016/j.heliyon.2022.e12570. eCollection 2022 Dec. Heliyon. 2022. PMID: 36643309 Free PMC article.

7

Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer.

Lerner SP, Tangen C, Svatek RS, Daneshmand S, Pohar KS, Skinner E, Schuckman A, Sagalowsky AI, Smith ND, Kamat AM, Kassouf W, Plets M, Bangs R, Koppie TM, Alva A, La Rosa FG, Pal SK, Kibel AS, Canter DJ, Thompson IM Jr; SWOG S1011 Trial Investigators. Lerner SP, et al. N Engl J Med. 2024 Oct 3;391(13):1206-1216. doi: 10.1056/NEJMoa2401497. N Engl J Med. 2024. PMID: 39589370 Free PMC article. Clinical Trial.

8

Correlation of Body Mass Index with Overall Survival Among Patients with Metastatic Hormone-sensitive Prostate Cancer: Analysis of Patient-level Data from SWOG-1216.

Swami U, Jo Y, Narang A, Plets M, Hage Chehade C, Gebrael G, Gupta S, Myint Z, Tangen C, Lara PN Jr, Thompson IM Jr, Hussain MHA, Dorff TB, Lerner SP, Agarwal N. Swami U, et al. Among authors: lerner sp. Eur Urol Oncol. 2024 Nov 8:S2588-9311(24)00241-4. doi: 10.1016/j.euo.2024.10.013. Online ahead of print. Eur Urol Oncol. 2024. PMID: 39521639

9

DNA Damage Response Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 Trial.

Iyer G, Tangen CM, Sarfaty M, Regazzi AM, Lee IL, Fong M, Choi W, Dinney CPN, Flaig TW, Thompson IM Jr, Lerner SP, McConkey DJ, Rosenberg JE. Iyer G, et al. Among authors: lerner sp. JCO Precis Oncol. 2024 Nov;8:e2400287. doi: 10.1200/PO.24.00287. Epub 2024 Nov 5. JCO Precis Oncol. 2024. PMID: 39499893

10

Eligibility and Endpoints for Clinical Trials in Trimodality Therapy for Bladder Cancer.

Singh P, Ballas L, Sonpavde GP, Chen RC, Bangs R, Bauman BC, Nagar H, Delacroix SE, Lerner SP, Efstathiou JA. Singh P, et al. Among authors: lerner sp. Bladder Cancer. 2024 Oct 23;10(3):199-213. doi: 10.3233/BLC-240036. eCollection 2024. Bladder Cancer. 2024. PMID: 39493817 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

336 results

Search Page

Filters